|
|
|
|
|
|
|
|
|
|
-
Arena Pharmaceuticals Q1 Loss Per Share $0.09 Vs. Loss $0.18 Prior Year; Provides Corporate Update
5/2/2013
|
|
|
-
Arena Pharma Says Begins Phase 1 Trial Of APD334 For Autoimmune Diseases
4/5/2013
|
|
|
-
Arena Pharmaceuticals Says Eisai Submits MAA For BELVIQ In Mexico
4/1/2013
|